



Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

October 17, 2022

BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a live conference call and webcast at 8:00 am ET on Tuesday, November 8, 2022 to review topline data from the Company's Phase 1b/2a GULLIVER-2 trial for liver cirrhosis.

Webcast Information

Galecto will host a live conference call and webcast at 8:00 am ET on Tuesday, November 8, 2022. Full details for the webcast are as follows:

Date: November 8, 2022
Time: 8:00 am Eastern Time
U.S. Dial-in Number: 1-877-704-4453
Int'l Dial-in Number: 1-201-389-0920
Conference ID: 13733763
Webcast: [Click Here](#)

A replay will be available on the [Events](#) portion of the Company's investor relation's website.

About the GULLIVER-2 Trial

The GULLIVER-2 trial ([NCT05009680](#)) is a Phase 1b/2a trial designed to assess the safety, tolerability, pharmacokinetics and potential activity of GB1211 in up to 54 participants. This study includes patients with decompensated cirrhosis (**Child-Pugh Classes B and C**).

Part 2 of the GULLIVER-2 trial is a Phase 2, randomized, double-blind, placebo-controlled trial in 30 patients that is designed to assess the effect of 12-week repeated dosing of oral GB1211 on a wide series of markers of hepatic function and structure in patients with decompensated cirrhosis (**Child-Pugh B**). Patients are randomized 1:1 to receive oral GB1211 100mg or placebo twice daily for 12 weeks.

Parts 1 and 3 of the GULLIVER-2 trial are open-label, single dose study parts designed to evaluate the safety and pharmacokinetics of GB1211 in patients with moderate to severe hepatic impairment (**Child-Pugh B and C, respectively**) and compare with matched healthy subjects.

About GB1211

Galecto is developing GB1211, an orally available and potent small molecule galectin-3 inhibitor. Galecto's initial target indications for GB1211 are liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and non-small cell lung cancer, a cancer indication with a high unmet need.

GB1211 demonstrated antifibrotic activity and anti-cancer effects in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 had a favorable tolerability profile and exhibited dose-dependent pharmacokinetics.

About Galecto

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.

Hans Schambye, CEO
Jon Freve, CFO
+45 70 70 52 10

Investors/US

Ashley R. Robinson
arr@lifesciadvisors.com
+1 617 430 7577

Media/EU

Sandya von der Weid
svonderweid@lifesciadvisors.com
+41 78 680 0538



